Theravance Biopharma Q2 2026: Narrower Loss, 11% YUPELRI Growth, and Zymeworks Deal on Track
TBPH sits 53% above its 52-week low of $11.045 on elevated volume (4.3× avg).
Summary
Theravance Biopharma's Q2 2026 results featured an 11% increase in YUPELRI collaboration revenue, a narrowed net loss, and a strong cash position. The pending acquisition by Zymeworks for $17.00 per share plus a CVR is expected to close in the second half of 2026.
Key Events · Earnings and Guidance · TBPH
-
Q2 2026 Financial Results
A net loss of $5.9 million, or $0.11 per share, compared to net income of $54.8 million in Q2 2025—a figure that included a $75.1 million one-time gain. Revenue reached $20.7 million, all from the YUPELRI collaboration.
-
YUPELRI Revenue Growth
Collaboration revenue rose 11% year-over-year to $20.7 million, fueled by 7% growth in U.S. net sales to $70.7 million and improved operating leverage.
-
TRELEGY Milestone Payment
GSK reported Q2 2026 TRELEGY net sales of approximately $1.0 billion, and there is high confidence in achieving the $100 million milestone payment from Royalty Pharma for full-year 2026.
-
Restructuring Progress
Operating expenses, excluding restructuring and transaction costs, decreased 35% year-over-year in Q2 2026. Full run-rate savings of approximately $70 million are expected in the second half of 2026.
Analysis · TBPH · Life Sciences
A solid quarter for Theravance Biopharma, with YUPELRI collaboration revenue climbing 11% to $20.7 million and operating expenses slashed 35% year-over-year thanks to restructuring. The net loss narrowed to $5.9 million—a sharp contrast to the prior year's profit, which was inflated by a one-time gain. Bolstered by $387.7 million in cash and no debt, the balance sheet remains robust. The pending $17.00 per share acquisition by Zymeworks is on course for the second half of 2026, and high confidence in a $100 million TRELEGY milestone payment adds near-term upside. Together, these results strengthen the value proposition for shareholders ahead of the acquisition vote.
At the time of this filing, TBPH was trading at $16.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $877.5M. The 52-week trading range was $11.05 to $21.03. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.